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Abstract Concentration-dependent electroinsertion of recombi- 
nant human membrane CD4 in human erythrocytes hows a sat- 
uration at an average of about 3,500 inserted CD4 epitopes per 
cell, detectable by flow cytometry. The erythrocyte recovery 
drops to 10% at this high level of electroinsertion. Experimentally 
an optimum for cell recovery and insertion rate was found at 
about 2,500 CD4 epitopes per red blood cell. In vitro stability 
assays by flow cytometry indicated a temperature- and medium- 
dependent decrease in the number of CD4 epitopes inserted per 
cell. This decrease is biphasic, with an exponential part during the 
first 24 h after electroinsertion followed by a much slower linear 
decay. 
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I. Introduction 
Human recombinant membrane CD4 (rmCD4), the high af- 
finity receptor for the HIV-1 envelope glycoprotein gp-120 on 
the surface of T-lymphocytes, electroinserted into human 
erythrocytes (RBC) and injected into the patient might be used 
as a therapy against AIDS [1-3]. Soluble forms of CD4 (sCD4) 
lacking the transmembrane portion did not fulfill the expecta- 
tion of blocking infection by patient isolates in vitro [4-7]. The 
short half-life of sCD4 in circulation [8,9] and the absence of 
membrane nvironment for the CD4 epitopes, among other 
reasons, led to the failure of sCD4 as a therapeutic agent 
against AIDS [10,11]. 
Subjected to a pulsed electric field, erythrocytes retain un- 
changed life spans in circulation [12]. RBCs bearing electroin- 
serted rmCD4 (RBC-rmCD4) or human glycophorin injected 
in mice and piglets also have the same half-life as normal RBC 
[13]. The RBC-rmCD4 were shown to bind gp-120 [14], to 
attach and internalize HIV- 1 particles in vitro, and form aggre- 
gates with HIV-infected Chinese hamster ovary fibroblasts ex- 
pressing p-120 [14] or with HIV-infected CEM cells [12]. It 
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appears thus, that RBC-rmCD4 as a long-lived carrier for CD4 
might provide a significant advantage over sCD4. 
A Phase I clinical trials pilot study in which autologous 
RBC-rmCD4 was injected into HIV-1 positive patients revealed 
a complex life span of the RBC-rmCD4 in circulation [3]. J25I- 
labeled rmCD4 was electroinserted into RBC and the RBC- 
rmCD4 were labeled with 5~Cr after the electroinsertion proc- 
ess. Radioactivity measurements of the in vivo stability of this 
system were made at different time points after infusion [3]. The 
51Cr-data confirmed an only slight decrease in the survival of 
the RBC-rmCD4s. In contrast, the 125I signal showed a rapid 
decrease during the first 3-4 days followed by a slow decrease 
parallel to the 51Cr decay. This observation raised the question 
of whether the 1251 decrease reflects clearance of 125I from the 
rmCD4 or loss of rmCD4 from the RBC-rmCD4. 
The potential efficiency of RBC-rmCD4 as a therapeutic 
agent depends on the total amount of inserted rmCD4 available 
in the circulation after infusion, as a potential decoy for HIV-1. 
A high number of CD4 epitopes in circulation may be achieved 
by either: (i) increasing the number of CD4 epitopes per RBC- 
rmCD4, or (ii) increasing the number of reinfused RBC- 
rmCD4. Since the volume of RBC-rmCD4 to be reinfused will 
be limited, the final number of reinfused RBC-rmCD4 depends 
on the percentage ofcells 'surviving' the process of electroinser- 
tion. 
We report here stability measurements on RBC-rmCD4, 
using flow cytometry, and rmCD4 concentration data leading 
to the optimization of the number of CD4 epitopes on the 
RBC-rmCD4 along with the highest achievable recovery of 
cells. 
2. Materials and methods 
2.1. Chemicals 
Chemicals were obtained from Sigma (St. Louis, MO, USA), ACS 
grade. The electroinsertion medium consisted of 137 mM NaCI, 2.7 
mM KCI, 10.1 mM Na2HPO 4and 1.8 mM KH2PO 4 adjusted to pH 8.8 
with NaOH. The wash buffer had the same composition but was ad- 
justed to pH 7.2 with HC1 (PBS 7.2). 
The anti-CD4 monoclonal ntibodies Leu3a (mouse IgG1) and fiuo- 
rescein isothiocyanate isomer I conjugated (Leu3a-FITC) were from 
Becton Dickinson Immunocytometry Systems (Mountain View, CA, 
USA). Negative control mouse antibodies IgG1 were provided by 
Amac Inc. (Westbrook, ME. USA). FITC-conjugated affinipure rabbit 
anti-mouse antibodies (RAMF) were from Jackson Immuno Research 
Laboratories (West Grove, PA, USA). 
Quantum simply cellular microbeads (QSC-beads, diam. 8 pm) for 
the quantitation ofantibodies on red blood cells (RBC) were provided 
by Flow Cytometry Standards Corp. (San Juan, Puerto Rico). Align- 
ment of the flow cytometer was carried out with Immunocheck beads 
(IC-beads, diam. 10 gtm) from Coulter Corp. (Hialeah, FL, USA). 
Adsol red cell preservation solution (PM) was from Baxter 
Healthcare Corp. (Fenwal Div., Deerfield, IL, USA). RPMI 1640 
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medium with L-glutamine (RPMI) and heat-inactivated fetal bovine 
serum (FBS) were from JRH Biosciences (Lenexa, KS, USA). 
2.2. Electroinsertion 
The electroinsertion device was the BTX T100 electroporation sys- 
tem and the pulse chamber consisted of the disposable sterile Electropo- 
ration cuvette plus with either 2 mm or 4 mm electrode gap and safety 
stand (all BTX Inc., San Diego, CA, USA). The applied voltage and 
the time constant (tile) of the exponential decay pulse were monitored 
by a BTX pulse checker electroporation monitor. 
Human erythrocytes (RBC) were separated from fresh whole blood 
of healthy donors by centrifugation with citric acid and dextrose (ACD) 
as anticoagulant. The plasma was collected, 1.2 ,urn filtered and later 
on used for RBC-rmCD4 cultures. The RBCs were washed three times 
with PBS 7.2 and once with electroinsertion medium. The RBC stock 
suspension had a final hematocrit of 0.82 + 0.02. 
Affinity purified, recombinant membrane CD4 obtained in our labo- 
ratory [15,16] was concentrated to final concentrations of 1-8 mg/ml 
(Bradford assay [17]) in PBS, pH 7.2, and stored at -70°C. The immu- 
nological activity of each rmCD4 sample was characterized in arbitrary 
fluorescence units per volume (units//A) by a quantitative immunofluo- 
rescent assay (QIFA) [18]. 
The rmCD4 stock was thawed for 1 h on ice, mixed with the RBC 
stock suspension (1:10, v/v) and incubated for 20 min on ice. The 
mixture was then transferred into the electroporation chamber and the 
temperature was raised over 10-15 min to 37°C, in a water bath. Four 
exponentially decaying electrical pulses were applied at 15 min inter- 
vals. Between the pulses the chamber was kept at 37°C in the water 
bath. The field strength used was 2.0 + 0.1 kV/cm and the pulse length 
was 1.1 + 0.1 ms. After the last pulse application the cells were kept 20 
min at 37°C and then washed several times with PBS 7.2 until the 
supernatant was hemoglobin free, 
The final pellet of rmCD4 bearing RBC (RBC-rmCD4) was resus- 
pended in 2 vols. of PM and stored at 4°C for further analyses and 
stability measurements. The entire procedure was performed under 
sterile conditions. Cell recovery was determined by using a Coulter 
MAXM (Coulter Corp., Miami, FL, USA) and is expressed as the 
percentage of the number of RBC in the initial RBC/rmCD4 mixture. 
As a control sample for the immunofluorescence assays, an aliquot 
of the RBC stock suspension was subjected to all steps of the described 
procedure without he addition of rmCD4. The mean fluorescence of 
the control RBC was the same whether the electric pulses were applied 
or not. Further control measurements concerning the quality of the 
electroinsertion, e.g. orientation of the rmCD4 in the membrane, were 
already described elsewhere [1,12]. 
2.3. Immunofluorescence assay 
To assay the stability of the immunologically active rmCD4 in the 
RBC membrane, 2 x 10 6 cells were washed once, incubated with 50 ng 
of Leu3a or isotypic control mouse IgG1 in a total volume of 50/11, 
washed, incubated with = 1/~g of the second antibody RAMF in 50 ¢tl, 
washed and resuspended in buffer for flow cytometric analysis. Leu3a 
competes for the same CD4 epitope as gp-120, the HIV envelope 
glycoprotein [19]. For the determination f the total number of CD4 
epitopes per RBC, control RBC, RBC-rmCD4 and QSC beads were 
labeled directly with 50 ng of Leu3a-FITC in a total volume of 50/11. 
All incubations were performed at room temperature for 30 rain and 
under saturation conditions. Every step was carried out in PBS 7.2. 
2.4. Flow cytometry 
Flow cytometric analysis was performed with a Coulter Epics Elite 
instrument (Coulter Corp., Hialeah, FL, USA). The FITC fluorescence 
emission was measured using a 525 nm band-pass filter after alignment 
of the instrument with IC beads. The standardization curve of fluores- 
cence intensity vs. the number of antibody binding sites was obtained 
at three different photomultiplier (PMT) voltages, one of which was the 
same used to measure the fluorescence of the labeled RBC-rmCD4. The 
histograms collected for analysis were: (i) 90 ° side scatter vs. forward 
scatter, and (ii) log of green fluorescence vs. number of cells. 
2.5. RBC-rmCD4 stability 
The stability of the immunologically active rmCD4 in the RBC mere- 
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Fig. 1. Number of binding-sites on Quantum simply cellular microbeads labeled with Leu3a-FITC vs. their mean fluorescence as measured at 
difference PMT voltages ~, 1500 V; ~Z, 1400 V; O, 1200 V. The inset shows the PMT voltage-independent li ear relationship between the mean 
fluorescence ratio and the number of binding sites that was used to determine the number of CD4 epitopes on similarly labeled RBC-rmCD4. The 
ratio was derived through division of each single mean fluorescence value by the mean fluorescence of the control beads population without any 
specific binding. The error bars represent the standard eviation. 
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brane was followed over several days by flow cytometric analysis. For 
this purpose the RBC-rmCD4 were stored under different conditions: 
(i) stock suspension i PM, hematocrit around 0.30, 4°C; (ii) diluted 
in PM, 4°C; (iii) diluted in RPMI/FBS, 4°C; (iv) diluted in RPMI/FBS, 
23°C; (v) diluted in RPMI/FBS, 37°C; (vi) diluted in plasma, 37°C. For 
samples ii-vi 5 x 10 7 cells were taken from the stock suspension, washed 
once with the appropriate medium, resuspended in 1 ml of the medium, 
transferred to 12-well plates and stored or cultured as described. Sam- 
ples were taken at certain time intervals and labeled with Leu3a or 
control IgG1 and RAMF. 
3.  Resu l ts  
3.1. Quantitation of epitopes and recovery 
The quantitation of CD4 epitopes on RBC-rmCD4 by flow 
cytometry is not straightforward since all standards available 
are not able to simulate RBCs exactly since they lack hemoglo- 
bin. The Quantum Simply Cellular standard used consists of a 
population of four highly uniform microbeads of the same size, 
having varying capacities to bind mouse monoclonal IgG anti- 
bodies. Included in the mixture is a blank population of mi- 
crobeads that has no specific binding capacity for mouse IgG. 
Measurement of these beads labeled with Leu3a-FITC similar 
to the RBC in the flow cytometer, using the same PMT-volt- 
age, shows five distinct peaks in the green histogram channels. 
The blank beads, with no binding capacity, have a higher mean 
peak channel than control mouse IgG1-FITC-labeled RBC- 
rmCD4. Thus, the determination f the number of binding-sites 
on the RBC, using the linear extrapolation of binding sites 
against mean peak channels of the similarly labeled QSC beads, 
as suggested by the manufacturer, is not possible. Lowering the 
PMT voltage in order to match the mean fluorescence of blank 
beads and non specific labeled RBC-rmCD4 does not increase 
accuracy. This is due to the decreased slope in the linear de- 
pendency of the mean peak channel upon the number of bind- 
ing-sites (see Fig. 1). 
Assuming that the quenching of fluorescence due to light- 
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Fig. 2. RBC-rmCD4 mean fluorescence ratio as a function of the 
rmCD4 concentration. The mean fluorescence ratio was calculated by 
dividing the mean fluorescence of specifically abeled RBC-rmCD4s by 
those of unspecifically labeled RBC-rmCD4s (Leu3a or IgGl and 
RAMF). The extrapolated curve is not based on a theoretical equation 
but ease the view of the two contrasting relationships ( ee Fig. 3). The 
error bars represent the standard eviation of at least hree independent 
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Fig. 3. Percentage RBC recovery as a function of the rmCD4 concentra- 
tion. The extrapolated curve is not based on a theoretical equation but 
ease the view of the two contrasting relationships (see Fig. 2). The error 
bars represent the standard eviation of at least hree independent 
electroinsertion experiments and duplicate labelings. 
channel of either specific or non-specific labeled RBC-rmCD4, 
we calculated the number of binding sites using the ratio 
of the mean fluorescence, e.g. RBC-rmCD4Leu3a_HTc/RBC- 
rmCD4xNVWTC. By doing so, we obtained with the beads' stand- 
ards a linear dependency of the number of binding sites upon 
the mean fluorescence, independent of the PMT voltage (see 
inset in Fig. 1). Using this standard curve we determined the 
number of CD4 epitopes on the RBC-rmCD4 up to 5,000. 
The number of CD4 epitopes determined by a quantitative 
immunofluorescent assay (QIFA) [18] increased linearly with 
the rmCD4 concentration in the range from l mg/ml to 8 mg/ml 
as measured by Bradford protein assay [17] using purified 
human IgG as a standard (data not shown). In addition, the 
number of CD4 epitopes electroinserted (RBC suspen- 
sion : rmCD4 solution = 9: 1, v/v) into the RBC plasma mem- 
brane was dependent on the rmCD4 batch used. Fig. 2 shows 
that the correlation between the number of CD4 epitopes on 
RBC-rmCD4 expressed in mean fluorescence ratios and the 
rmCD4 concentration yields a saturation effect at about 3,500 
rmCD4 epitopes per RBC. Here we used the more sensitive 
indirect staining with Leu3a or IgG1 and RAMF. 
At the same time, the recovery of the RBC after the electro- 
insertion process decreases with higher CD4 concentrations 
(see Fig. 3). The recovery was determined by cell counts and is 
expressed as a percentage of the initial number of RBC. 
The extrapolated curves help us to understand the two proc- 
esses that occur during the electroinsertion, namely implanting 
rmCD4 into the RBC membrane on the one hand and RBC 
lysis on the other, rmCD4 concentrations between 2 and 3 
mg/ml ed to the insertion of an optimal number of CD4 epi- 
topes per RBC (between 2,000 and 3,000) to the best possible 
cell recovery. 
3.2. Stability of RBC-rmCD4 in vitro 
In order to enhance the sensitivity of the in vitro stability 
assays, the RBC-CD4 were also indirectly labeled with Leu3a 
or control IgG1 and RAMF. We used the ratio of the mean 
fluorescence (RBC-CD4L~u3~RAMF to RBC-CD41gGI/RAMF) in 
order to eliminate sensitivity fluctuations in the flow cytometer 
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Fig. 4. CD4 epitopes on a single representative RBC-rmCD4 popula- 
tion at 4°C in different media as a function of time, described by the 
mean fluorescence ratio after indirect labeling (see Fig. 2). The error 
bars indicate the standard eviation of duplicate labeling, both specific 
and unspecific. The extrapolated curve is fitted using y = a× 
exp (-b × t) + c + d× t. ~, RBC-rmCD4 in PM, cell density 3 × 10 9 
cells/ml; V, in PM, 5 × 10 7 cells/ml; <>, in RPMI/FBS, 5 × 10 7 cells/ml. 
signal. Every labeling was duplicated and averaged (inclusive 
standard eviation). At the beginning, the stability of the CD4 
electroinsertion was checked at 4°C in Adsol red cell preserva- 
tion solution (PM), a commonly used solution for long-term 
storage in blood banks, and at 37°C in RPMI 1640 medium 
supplemented with fetal bovine serum (5%, RPMI/FBS). Seeing 
a significant difference in the rate of disappearance of exposed 
CD4 epitopes on RBC-rmCD4 under these conditions, we in- 
vestigated the stability of insertion under different storage or 
culture conditions. In a final series of experiments he temper- 
ature, the nature of the medium and the cell density dependence 
of the insertion stability were investigated. 
RBC-rmCD4 were stored at 4°C in PM at a hematocrit of 
around 0.30 (ca. 3 x 109 cells/ml, PMhigh) and in PM (PMiow) or 
RPMI/FBS at a density of 5 x 107 cells/ml. Fig. 4 shows the 
decrease of the mean fluorescence ratio of a RBC-rmCD4 pop- 
ulation with time. In PMh~gh and in RPMI/FBS this dependence 
is curvilinear. The best fit of these data points is obtained by 
using a combination of a single exponential nd a linear decay. 
The stability of insertion appears completely different when 
RBC-rmCD4 are stored diluted in PM to the same density as 
in the RPMI/FBS storage. After an immediate drop, the mean 
fluorescence ratio remains constant during the observation pe- 
riod. In several experiments his constant value was about 
30 + 3% of the value at t = 0. In RPMI/FBS the stability was 
always better than in VMhig  h and the mean fluorescence ratio 
never dropped below the 30% value seen in PM~o w. Moreover 
the observed number of CD4 epitopes in PMhig h always 
dropped below this 30% value after 3-5 days. 
Fig. 5 shows the loss of CD4 epitopes on RBC-rmCD4 in 
RPMI/FBS at the same densities (5 x 107 cells/ml) but different 
temperatures. The combination of a single exponential nd a 
linear decrease also led to the best fit of the data points. With 
increasing temperature the exponential part becomes increas- 
ingly prevailing but even at 37°C a single exponential curve fit 
is never satisfying. 
Culture of the RBC-rmCD4 at 37°C in plasma improved the 
stability slightly in comparison to RPMI/FBS (see Fig. 5). The 
rmCD4 in vitro stability in both media is clearly better than that 
of sCD4 in vivo [8], mainly as the entire signal does not disap- 
pear exponentially. The [125I]rmCD4 stability in vivo [3] is even 
better than the flow cytometric data in vitro suggest. 
Considering the complex nature of this system and that the 
flow cytometer measurements are performed 1.5 h after the 
sample has been taken, we cannot expect o clearly separate the 
two phases of the decay in a mathematical way. Therefore we 
characterize the in vitro stability by using a 'pseudo' half time, 
ts0~. These tso~ values indicate the time, in days, when the mean 
fluorescence ratio has dropped to 50% of the initial value. Due 
to the thereby neglected linear phase the stability of the rmCD4 
appears maller than it is in reality but enables us to look at a 
single parameter for comparison. Table 1 summarizes the ts0~ 
values of the different RBC-rmCD4 storage/culture conditions. 
4.  D iscuss ion  
Based on a standard microbeads population having different 
numbers of binding sites, we determined the number of CD4 
epitopes on RBC-rmCD4 produced by electroinsertion. It was 
assumed that the fluorescence-quenching effect of the RBC is 
proportional to the total emitted fluorescence light of the cells. 
We eliminated this correction factor by calculating the mean 
fluorescence ratio of specifically and non-specifically labeled 
cells. It appears that this assumption leads to an underestima- 
tion of the number of epitopes. The visibility of the fluorescence 
emitted by labeled rmCD4 that has migrated into the grove of 
the disk is definitely lower than the fluorescence of labeled 
rmCD4 on the rest of the RBC plasma membrane [20]. There- 
fore the average effective fluorescence per protein ratio is 
smaller on Leu3a-FITC bound to RBC-rmCD4 than bound to 
the white spherical standards beads. Although this method is 
an underestimation t provides us with a minimum number of 
CD4 epitopes on the cell surface. 
The optimization of the rmCD4 electroinsertion in RBC in 
the direction of a high number of CD4 epitopes per cell and 
high RBC recovery shows a very interesting relationship. The 
reason for the saturation effect in the number of CD4 epitopes 
with increasing rmCD4 concentration is most likely the limited 
expandability of the RBC membrane, as suggested by the fol- 
lowing calculation: one CD4 molecule requires an area of 1.54 
nm 2, assuming a radius of r = 0.7 nm for the transmembrane 
helix [21]. 5,000 CD4 epitopes need then 8 × 10 3 nm 2. The aver- 
age surface area of an RBC is about 140 × 10 6 nm 2 [22]. The 
maximal inserted 5,000 CD4 molecules increase the RBC sur- 
face area by 0.006%. In addition we have to consider two facts: 
(i) the number of CD4 epitopes per RBC determined by flow 
Table 1 
'Pseudo' half-decay time ts0 ~ for the loss of immunologically active 
rmCD4 on RBC-rmCD4 stored under different conditions, as meas- 
ured by flow cytometry after indirect labeling with Leu3a nd RAMF 
Medium T (°C) ts0 ~ (days) Number of 
experiments 
PMh~gh 4 4.2 --+ 1.2 35 
RPMI/FBS 4 > 10 4 
RPMI/FBS 23 2.8 + 0.9 4 
RPMI/FBS 37 0.71 + 0.16 33 
Plasma 37 0.93 _+ 0.21 6 
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Fig. 5. CD4 epitopes on a single representative RBC-rmCD4 popula- 
tion at different emperatures and media as a function of time, ex- 
pressed by the mean fluorescence ratio (see Fig. 4). O, 4°C; ±, 23°C; 
':~, 37°C; all in RPMI/FBS; (2, 37°C in plasma; cell density for each is 
5 × 10 7 cells/ml. 
cytometric analysis is an underestimation for the reasons 
shown, and (ii) we detect only the immunologically active 
rmCD4. The protein is purified and detergent free, and there- 
fore we must assume a percentage of denatured protein in the 
rmCD4 concentrates. Some of it may not be amenable to inser- 
tion due to denatured transmembrane structure, but along with 
active rmCD4 we also insert rmCD4 with denatured antibody 
binding sites. We also have to consider that the tertiary struc- 
ture of the extracellular part of the rmCD4 has to squeeze itself 
amongst he very dense glycocalyx of the RBCs and every 
integral membrane protein is usually surrounded by a number 
of closely adjacent lipid molecules [23]. Therefore we believe the 
increase in the RBC surface by inserted rmCD4 may reach up 
to 1%. Investigations to determine the elasticity of the erythro- 
cyte membrane have been described in the literature: the best 
comparable model to rmCD4 electroinsertion may be the deter- 
gent-like auto-insertion f apolipoprotein into the bilayer mem- 
brane [24]. Even though this study focusses on many different 
quantitative aspects, the occurence of lysis is never related to 
the percentage extension of membrane expansion. The majority 
of the articles describe shape changes induced in RBC by ex- 
panding only the outer leaflet of the bilayer through the inser- 
tion of lipids or lipid analogs, e.g. monopalmitoyl phosphati- 
dylcholine [25]. Others tried to mechanically expand small areas 
of the membrane of osmotically preswollen RBC. They found 
immediate lysis with about a 3% [26] or 2.6% [27] area increase, 
and lysis within 20-30 s with a 2% area increase [26]. The RBC- 
rmCD4 are washed after electroinsertion for more than 1 h. 
This period of time gives even those RBC-rmCD4s which expe- 
rience a lesser expansion of their membrane enough time to 
lyse. Gradual reduction of the volumes of RBC-rmCD4 pellets 
observed throughout the post-wash process, until no further 
lysis occurs, supports our explanation. Therefore, the existance 
of an upper limit of the number of inserted proteins, without 
destruction of the integrity of the membrane, is most likely. The 
RBC, into the plasma membrane of which more than 5,000 
CD4 epitopes have been inserted, lyse. This evidence is also 
supported by the decrease in the RBC recovery with higher 
rmCD4 concentrations u ed during the electroinsertion. It 
seems that the majority of the RBC population withstands 
rmCD4-insertion at the level of 2,000-3,000 epitopes per cell. 
At the appropriate rmCD4 concentrations we obtain a high 
RBC recovery. 
The immunofluorescence data do not give information about 
the fate of the lost rmCD4. The reason why about 70% of the 
inserted CD4 epitopes are lost instantly when we store the 
RBC-rmCD4 diluted in PM at 4°C is not clear. Possibly, part 
of the cells lose rmCD4 spontaneously under these conditions, 
until somehow an equilibrium within the medium has been 
reached. In this case the equilibrium should shift to a different 
value at different densities, but we found the same instant loss 
of CD4 epitopes (about 70%) at double and quadruple cell 
densities (data not shown). Performing standard blood bank 
storage at a high hematocrit (30%) and 4°C, the decrease ap- 
pears linear for a portion of the curve and exponential for the 
other. The Adsol red cell preservation solution used is certainly 
optimized in its chemical composition to maintain transfusion- 
able conditions of RBCs during storage for up to 30 days at 
4°C. Nonetheless it may only be effective at standard high 
hematocrits but not in dilute suspensions. 
The temperature dependence of the rmCD4 stability in 
RPMI/FBS suggests, on the other hand, that the loss of the 
rmCD4 signal may be related to the metabolism of the cells. 
The kinetics of the loss of CD4 epitopes increases with higher 
temperatures. This indicates an active process removing the 
rmCD4 out of the membrane. A reason therefore may be the 
above-discussed extension of the membrane due to the inserted 
rmCD4. The higher the temperature the more RBCs are able 
to enforce a relaxation of the membrane by removing rmCD4, 
as seen in the exponential part of the stability curves. However 
if this 'active' process is delayed by a lower temperature or a 
more native culture condition, as in plasma for example, a 
higher percentage of inserted rmCD4 remains stable in the 
membrane and the signal decreases only due to cell loss. Fig. 5 
clearly shows that the in vitro studies seem to confirm the 
[~25I]rmCD4 measurements conducted in vivo [3]. Due to this 
similarity we conclude that the flow cytometric observations 
indeed reflect a loss of rmCD4 from the membrane and not just 
denaturation of its epitopes. The amount of rmCD4 that is 
stably inserted in vivo, is even better than in vitro [3]. We believe 
this to be caused by the optimal conditions for the RBC- 
rmCD4 that keep the cells more tolerant o long-term mem- 
brane expansion. Further studies to understand this phe- 
nomenon of rmCD4 loss from RBC-rmCD4 better are under 
investigation i our laboratory. 
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